2016 Life Sciences Outlook

In biomanufacturing, biotechnology, Life sciences, manufacturing, pharmaceutical by GenerisLeave a Comment

There are many changes on the horizon for the life sciences industry. To help pharmaceutical manufacturers navigate the changes ahead Clarkston Consulting has generated the report below to highlight some of the trends and changes that will have the greatest impact on the industry at large. Clarkston Consulting is a leading management, operations & implementation consultancy firm that specializes in the life sciences industry. The report outlines the current state of the industry by looking at the regulatory environment, changes brought on by mergers, acquisitions, and divestitures, serialization challenges and the state of high value biologics, specialty and orphan drugs.  The whitepaper then examines factors that will have the greatest impact on the industry in the years to come and provides insights on how the industry will be able to successfully respond. Explore strategies to overcome the challenges and take advantage of the opportunities in internal manufacturing, external manufacturing, operational excellence, quality management and compliance at the American Biomanufacturing Summit 2016!

Read More →

The Implications of a Changing Healthcare Environment

In manufacturing, medical device, medtech, mfg, siemens by GenerisLeave a Comment

An Interview with Siemens Healthcare Diagnostics’ Dr. James Donnelly. The medical device industry has achieved significant growth over recent years, with the industry expected to generate $365 billion in sales by the end of 2015, and $460 billion by 2018 (information sourced from TÜV SÜD). The initial and continued success of a medical device is dependent on the value it brings to the delivery of healthcare, where there is a need to reduce waste in an evolving regulatory and reimbursement climate. Prior to his speaking engagement at the upcoming American Medical Device Summit 2015 in Chicago next week, we had the opportunity to sit down with James Donnelly ,Ph.D., Chief Scientific Officer, Global VP, Medical, Scientific & Statistical Affairs, Siemens Healthcare Diagnostics to gather his perspective on the medical device industry in the U.S., and understand how changes to the healthcare system will influence the industry moving forward. Donnelly has been with Siemens for more than eight years, beginning as Global Vice President of Medical, Clinical and Statistical Affairs. He is passionate about integrating customer input, quality, and innovation into the design of products. He also believes the customer must be an active partner in product lifecycle management and that innovation without purpose will not consistently add value to the healthcare system. Jim, how would you describe the current healthcare environment in the U.S. for medical devices? The current healthcare spend is not sustainable. We spend too much on healthcare delivery without the expected return in value. The healthcare system and its stakeholders are all experiencing significant …

Read More →